longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Caris Life Sciences

CAI

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 85.07, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 58/602, the industry Median -2.33.

85.07xP/E
$31.65Stock price
$0.37Earnings per share
85.07xP/E
Stock price$31.65Earnings per share$0.37

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-10.59x
Typical range
-11.33x–-9.10x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
022446688

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
CAIUSCaris Life Sciences
85.07x132.37%$8.94B
VCELUSVericel
82.01x72.66%$1.99B
PHARUSPharming Group NV
81.96x1,050.00%$762.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.